Skip to content

"MEMODIO_APP@CARE" The first multi-domain app for people with mild cognitive impairment and mild dementia - a pilot study.

"MEMODIO_APP@CARE" The first multi-domain app for people with mild cognitive impairment and mild dementia - a pilot study. - MEMODIO_APP@CARE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00033494
Enrollment
120
Registered
2024-02-09
Start date
2024-01-29
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F06.7 F00 F01

Interventions

Group 1: Intervention group In addition to standard care: Implementation of an app-based multi-domain intervention with brain training, sports program, nutritional adjustment, optimization of risk fac

Sponsors

memodio GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Diagnosis of either Mild Cognitive Impairment F06.7 or Mild Dementia F00, F01 • For MCI: MoCA Scores 21-25 OR Demtect-Score: 10 - 13 • For Mild Dementia: MoCA-Scores 14-20 OR Demtect-Score: 6-9 • Access to a smartphone or a tablet with internet connection • Ability to use smartphone apps of medium complexity (e.g. Whatsapp, Mail, Internet-Browser, etc.) • Ability to understand, read and write German • Age >18 years

Exclusion criteria

Exclusion criteria: • Any uncontrolled medical or neurological/neurodegenerative condition (other than MCI/ dementia) during the past 12 months that, in the opinion of the investigator, might be a contributing cause of the subject’s cognitive impairment (e.g., malignant disease, severe depression, substance abuse, vitamin B12 deficiency, abnormal thyroid function, acute stroke, head trauma) • Severe dementia (MoCa Score <14 OR Demtect-Score <6 OR other scores: according to individual recommendations) • Severe sensory impairment (vision, hearing) that makes app usage impossible • History or active / planned usage of comparable digital therapeutics • Other circumstances that make app usage impossible (e.g. planned surgery or cardiovascular intervention) • Any medications that, in the opinion of the investigator, may contribute to cognitive impairment, impair the subject’s ability to perform cognitive testing or complete study procedures. • If on prescribed medication for dementia: dosage has to be constant for 3 months for memantine, 8 weeks for Gingko biloba and 1 month for Acetylcholinesterase-inhibitors before inclusion in the study and/or planned change of dosage or medication regimen during the course of the study interval

Design outcomes

Primary

MeasureTime frame
Cognitive abilities (MoCA, Montreal Cognitive Assessment)

Secondary

MeasureTime frame
(Instrumental) Activities of daily living (Amsterdam iADL) Quality of life (Demqol, Dementia quality of life) Activity level (PAQ50+, Physical Activity Questionnaire in the over-50 Population)

Countries

Germany

Contacts

Public ContactGereon Nelles

NeuroMed Campus

praxis@neuromed-campus.de+49 221 943812-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026